Opinion
Video
Long-term Safety of JAK Inhibitors in Atopic Dermatitis
Key Takeaways
- Long-term upadacitinib data reveal sustained efficacy and safety, offering insights beyond short-term studies for atopic dermatitis management.
- Comparisons with other JAK inhibitors highlight differences in long-term outcomes, influencing clinical decision-making.
Following a review of findings from the LEVEL UP study, an expert on atopic dermatitis shares what we’ve learned from long-term data on upadacitinib and JAKi.
Video content above is prompted by the following:
- Are there any learnings from long-term upadacitinib data that were not seen in short-term data?
- What about short vs long-term data with other JAKi?
- How do they impact your use of JAKi for atopic dermatitis?
Related Videos
Related Content
